"Viking Therapeutics' Breakthrough Weight-Loss Drug Outperforms Competitors"

Viking Therapeutics' experimental weight-loss drug has shown promising results in a mid-stage trial, with patients on the highest dose losing an average of about 14.7 percent of their body weight after 13 weeks, outperforming current market-leading drugs like Ozempic and Mounjaro. The news caused Viking's stock price to soar by more than 70 percent, signaling potential competition for Eli Lilly and Novo Nordisk in the obesity and diabetes drug market. However, further late-stage trials are needed for FDA approval, and adverse events such as nausea and vomiting were reported.